Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
04/2003
04/02/2003EP1297117A1 Polynucleotides encoding human serine proteases
04/02/2003EP1297012A2 Novel fibroblast growth factors and nucleic acids encoding same
04/02/2003EP1297011A1 The t-cell protein tzon7, peptides and antibodies derived therefrom and uses thereof
04/02/2003EP1297005A2 Immunisation against chlamydia pneumoniae
04/02/2003EP1296998A2 Hcv variants
04/02/2003EP1296724A1 Bioadhesive composition and methods of preparation and use
04/02/2003EP1296720A2 Poliovirus replicons encoding therapeutic agents and uses thereof
04/02/2003EP1296714A2 Methods for enhancing antibody-induced cell lysis and treating cancer
04/02/2003EP1296712A2 Hiv-1 vaccines and screening methods therefor
04/02/2003EP1296711A2 Human papilloma virus treatment
04/02/2003EP1296699A1 Therapeutic agents - iii
04/02/2003EP1296698A1 Therapeutic agents - ii
04/02/2003EP1296697A1 Therapeutic agents - i
04/02/2003EP1296648A1 Micellar pharmaceutical compositions for buccal and pulmonary application
04/02/2003EP1296647A2 Polymeric micelle compositions
04/02/2003EP1296552A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5
04/02/2003EP1083886B1 Drug delivery system comprising a tightly compacted solid medicament stock
04/02/2003EP1080206B1 Generation of multiple gene products from chimeric fusion proteins by cleavage with endoproteases
04/02/2003EP0702518B1 Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
04/02/2003EP0610427B1 Tgf-beta type iii receptor, cdna encoding it and uses therefor
04/02/2003EP0566732B1 Adeno-associated virus-2 basal vectors
04/02/2003CN1408022A Recombinant adenoviruses for sodium/iodide symporter (NIS)
04/02/2003CN1407873A 医疗装置 Medical devices
04/02/2003CN1104501C Modified human C3 proteins
04/01/2003WO2002029054A1 Novel protein, process for producing the same and use thereof
04/01/2003US6541661 Inhibitors of histone deacetylase
04/01/2003US6541621 Hypoxia inducible promoter
04/01/2003US6541616 Exterior membrane; nucleotide sequence; induction immunology response
04/01/2003US6541459 Soluble herpesvirus glycoprotein complex vaccine
04/01/2003US6541458 Sequence of the capsid gene and a corresponding cDNA sequence, of a dominant FCV strain called FCV 431.
04/01/2003US6541457 Mammalian IAP gene family, primers, probes and detection methods
04/01/2003US6541255 Engraftable human neural stem cells
04/01/2003US6541248 Genome comprising nucleotide sequence encoding an anti-sense RNA or ribozyme; cleavage of a second nucleotide sequence which encodes a polypeptide; use in gene therapy
04/01/2003US6541244 Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
04/01/2003US6541221 For the identification, isolation, and/or expression of genes undiscoverable by current methods; use to isolate nucleic acids coding for proteins, including transmembrane proteins, and in research of human diseases and development
04/01/2003US6541219 Therapeutic Gene
04/01/2003US6541012 System for the production of AAV vectors
04/01/2003US6541010 Alphavirus RNA replicon systems
04/01/2003US6541003 An immunizing formulation comprising a plasmid encoding an attenuated, doxycycline-inducible proviral molecular clone of the human immunodeficiency virus type 1, and a pharmaceutical carrier
04/01/2003US6540995 Administering into the solid tumor of a cancer patient, a capsule encapsulating cytochrome P450 producing cells, and the capsule containing a porous membrane to protect the cells from immune system, allows prodrug to pass into the capsule
04/01/2003CA2424777A1 Novel protein, process for producing the same and use thereof
03/2003
03/27/2003WO2003025570A1 Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same
03/27/2003WO2003025228A1 Methods and compositions for treating hcap associated diseases
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025195A2 Nucleic acid constructs for the delivery of polynucleotides into dna-containing organelles,and uses thereof
03/27/2003WO2003025191A2 Pseudotyped retroviral vector system
03/27/2003WO2003025190A1 Tumor-specific promoter and use thereof
03/27/2003WO2003025189A2 A packaging complementation cell-line for sv-40 vectors
03/27/2003WO2003025187A2 Improvement of gene expression in vectors
03/27/2003WO2003025183A2 Random integration of a polynucleotide after in vivo linearization
03/27/2003WO2003025179A1 Novel polypeptide, dna thereof and use of the same
03/27/2003WO2003025174A2 Regulation of human mrp1-like protein
03/27/2003WO2003025167A2 Cultured stromal cells and uses thereof
03/27/2003WO2003025162A2 Regulation of human prolyl 4-hydroxylase alpha subunit precursor
03/27/2003WO2003025147A2 Novel polynucleotides and proteins encoded thereby
03/27/2003WO2003025140A2 Transductin-1 and transductin-2 and applications to hereditary deafness
03/27/2003WO2003025139A2 Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
03/27/2003WO2003025120A2 Clasp membrane proteins
03/27/2003WO2003025119A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
03/27/2003WO2003025003A2 Hiv-gag codon-optimised dna vaccines
03/27/2003WO2003024502A2 Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
03/27/2003WO2003024478A1 Treatment of central nervous system disorders by use of pdgf or vegf
03/27/2003WO2003024384A2 Improved methods for treatment with viral vectors
03/27/2003WO2003024312A2 Cell therapy system
03/27/2003WO2002098356A3 Ppp2cs as modifiers of the p53 pathway and methods of use
03/27/2003WO2002090551A3 Self-containing lactococcus strain
03/27/2003WO2002087496A3 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002078607A3 Mucin peptide with immunoenhancing properties
03/27/2003WO2002068633A3 Compositions and methods relating to lung specific genes and proteins
03/27/2003WO2002064799A3 Optimized messenger rna
03/27/2003WO2002059291A3 Biological organism for preparing pharmaceutical compositions for treating mammals
03/27/2003WO2002059270A3 Methods and compositions for expressing polynucleotides specifically in smooth muscle cells in vivo
03/27/2003WO2002055100A3 Method and composition for inhibition of tumor growth and enhancing an immune response
03/27/2003WO2002048358A3 Regulation of human chemokine-like receptor
03/27/2003WO2002046403A3 Regulation of human patched-like protein
03/27/2003WO2002044374A3 Flea gaba receptor subunit nucleic acid molecules, proteins and uses thereof
03/27/2003WO2002038773A3 A human phospholipase c and uses thereof
03/27/2003WO2002034201A3 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
03/27/2003WO2002024640A3 Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
03/27/2003WO2002022817A3 Nuclear receptor l66 and methods of use
03/27/2003WO2002018954A9 Inhibition of cmv infection and dissemination
03/27/2003WO2002016419A9 Progression suppressed gene 13 (psgen 13) and uses thereof
03/27/2003WO2002011667A3 Pharmaceutical compositions and methods useful for modulating angiogenesis
03/27/2003WO2002005857A3 Phosphatonin-related gene and methods of use thereof
03/27/2003WO2002000692A3 Pd-l2 molecules: pd-1 ligands and uses therefor
03/27/2003WO2001092548A3 Vaccine and gene therapy vector and methods of use thereof
03/27/2003WO2001079557A3 Gtp-binding protein useful in treatment and detection of cancer
03/27/2003WO2001062954A3 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
03/27/2003US20030061628 Nucleotide sequences coding polypeptide for use in controlling gene expression and treating genetic disotders
03/27/2003US20030061627 Polynucleotide
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060615 Novel Bak binding protein, DNA encoding the protein, and methods of use thereof
03/27/2003US20030060613 Protein for use in the treatment of bone, tumor and inflammatory disorders
03/27/2003US20030060604 Apolipoprotein agonist for use in the treatment of dyslipidemia
03/27/2003US20030060603 Generation of preferential antibodies in vertebrates; obtain cells, transfrom with expression vector coding antibody, express vector, recover antibody
03/27/2003US20030060478 Treatment of dyskinesia
03/27/2003US20030060444 In which an effector cell is transformed with DNA coding for chimeric receptor containing two or more cytoplasmic signalling components derived from tetraspan-transmembrane protein or antigens; anticancer agents
03/27/2003US20030060443 Inhibition of apoptosis by the expression of antisense RNA of caspase-3
03/27/2003US20030060442 Immunostimulatory cyktokines include interleukins as antitumor agents, dervived from dendritic cells modified via viral vector transduction/centrifugation
1 ... 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 ... 870